What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Martine Piccart mainly investigates Internal medicine, Breast cancer, Oncology, Surgery and Chemotherapy.
Her Internal medicine research focuses on subjects like Gynecology, which are linked to Performance status and Randomized controlled trial.
Her work deals with themes such as Chemotherapy regimen, Disease and Gene expression profiling, which intersect with Breast cancer.
Her Oncology research includes themes of Trastuzumab, Anthracycline, Estrogen receptor, Exemestane and Adjuvant therapy.
Her Surgery research is multidisciplinary, incorporating perspectives in Hormonal therapy, Adverse effect and Ovarian cancer.
Martine Piccart has included themes like Gastroenterology and Regimen in her Chemotherapy study.
Her most cited work include:
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2040 citations)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (1946 citations)
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis (1574 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery.
The concepts of her Breast cancer study are interwoven with issues in Cancer research and Disease, Pathology.
Her research in Oncology tackles topics such as Anthracycline which are related to areas like Taxane.
Her Cancer study incorporates themes from MEDLINE and Intensive care medicine.
The Chemotherapy study combines topics in areas such as Regimen and Ovarian cancer.
She most often published in these fields:
- Internal medicine (69.77%)
- Breast cancer (65.12%)
- Oncology (57.99%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (69.77%)
- Breast cancer (65.12%)
- Oncology (57.99%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Trastuzumab and Cancer.
Her study in Chemotherapy, Metastatic breast cancer, Hazard ratio, Pertuzumab and Early breast cancer is carried out as part of her studies in Internal medicine.
Her research integrates issues of Cancer research, Clinical endpoint, Clinical trial, Disease and Radiation therapy in her study of Breast cancer.
She specializes in Oncology, namely Adjuvant.
Martine Piccart interconnects Neoadjuvant therapy and Proportional hazards model in the investigation of issues within Trastuzumab.
Her Cancer research focuses on Aromatase inhibitor in particular.
Between 2017 and 2021, her most popular works were:
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (340 citations)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (216 citations)
- Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. (110 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Her primary areas of study are Internal medicine, Breast cancer, Oncology, Chemotherapy and Trastuzumab.
Martine Piccart is interested in Letrozole, which is a field of Breast cancer.
Her study in the field of Adjuvant also crosses realms of In patient.
Her Chemotherapy research integrates issues from Meta-analysis, Immunotherapy, Anthracycline and Early breast cancer.
Her Trastuzumab research incorporates themes from Mastectomy, Breast surgery and Circulating tumor cell.
Her Clinical trial research is multidisciplinary, incorporating elements of Cancer and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
